Abstract
The COVID-19 pandemic has revealed the importance of virus genome sequencing to guide public health interventions to control virus transmission and understand SARS-CoV-2 evolution. As of July 20th, 2021, >2 million SARS-CoV-2 genomes have been submitted to GISAID, 94% from high income and 6% from low and middle income countries. Here, we analyse the spatial and temporal heterogeneity in SARS-CoV-2 global genomic surveillance efforts. We report a comprehensive analysis of virus lineage diversity and genomic surveillance strategies adopted globally, and investigate their impact on the detection of known SARS-CoV-2 virus lineages and variants of concern. Our study provides a perspective on the global disparities surrounding SARS-CoV-2 genomic surveillance, their causes and consequences, and possible solutions to maximize the impact of pathogen genome sequencing for efforts on public health.
One-Sentence Summary The causes, consequences and possible solutions for disparities in genomic surveillance observed in the COVID-19 pandemic.
Competing Interest Statement
NDG is an infectious diseases consultant for Tempus Labs. MAS receives grants and contracts from the National Institutes of Health, the US Food & Drug Administration, the US Department of Veterans Affairs and Janssen Research & Development. OGP has undertaken work for AstraZeneca on SARS-CoV-2 classification and genetic lineage nomenclature.
Funding Statement
Internal Fondsen KU Leuven/Internal Funds KU Leuven, Grant No. C14/18/094 (GB)
Research Foundation, Flanders, “Fonds voor Wetenschappelijk Onderzoek, Vlaanderen” G0E1420N, (GB)
Research Foundation, Flanders, “Fonds voor Wetenschappelijk Onderzoek, Vlaanderen”, G098321N (GB)
National Institutes of Health F31 AI154824 (GWH, MAS)
National Institutes of Health R01 AI153044 (MAS)
National Institutes of Health U19 AI135995 (MAS)
Oxford Martin School, EUH2020 project MOOD (MUGK)
Branco Weiss Fellowship (MUGK)
Rockefeller Foundation (MUGK)
Google.org (MUGK)
Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (NDG)
Centers for Disease Control and Prevention (CDC) Contract # 75D30120C09570 (NDG)
Oxford Martin School (OGP)
Wellcome Trust (NRF)
Royal Society Sir Henry Dale Fellowship 204311/Z/16/Z (NRF)
Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0) (http://caddecentre.org/) (NRF)
NDG is an infectious diseases consultant for Tempus Labs. MAS receives grants and contracts from the National Institutes of Health, the US Food & Drug Administration, the US Department of Veterans Affairs and Janssen Research & Development. OGP has undertaken work for AstraZeneca on SARS-CoV-2 classification and genetic lineage nomenclature.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ Co-senior authors
Data Availability
Data used in this study can be found in this GitHub repository: https://github.com/andersonbrito/paper_2021_metasurveillance
